Hematology

Phase 1b/2 data of durvalumab plus danvatirsen show doubled response rate compared to previous studies with durvalumab alone in refractory head and neck cancer

Mount Sinai team reports that the presence or absence of protein NR2F1 can indicate whether a patient's cancer cells are dormant or likely to relapse

Positive trial results with filgotinib in psoriatic arthritis and ankylosing spondylitis published in The Lancet

MM-121 did not improve progression free survival in patients with non-small cell lung cancer; company to provide pipeline review update on November 7

Revolution Medicines acquires Warp Drive Bio to expand drug discovery portfolio focused on frontier oncology targets

MEI Pharma and BeiGene announce collaboration to evaluate ME-401 in combination with Zanubrutinib in patients with B-cell malignancies

Scripps scientists find new lead to combat low platelet counts

Agena, PerkinElmer partnership emphasizes quality, speed and sensitivity in liquid biopsy

Beginning with a story about Salk researchers finding a ‘master control switch' for aggressive breast cancer, we give you a quick roundup of recent breast cancer news in honor of Breast Cancer Awareness Month

FDA approves Genentech’s Hemlibra (emicizumab-kxwh) for hemophilia A without Factor VIII inhibitors

CytoSen Therapeutics and KBI Biopharma enter into strategic partnership to manufacture NK cells and nanoparticles

Fred Hutchinson researchers find that cancer cells evade immunotherapy by hiding a telltale marker, suggesting a possible way to prevent relapse